Opus Genetics price to book ratio IRD

Market value divided by the book value of the company's net assets, since 2024.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 23.1×; May 2026
Peer median: 2.2×

Opus Genetics' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in May 2026, at 23.1×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	23.1×	20.2×	56.5×
2025	23.3×	0.9×	27.3×
2024	1.1×	0.7×	1.1×

Against its peers

Companies in Drug Manufacturers - General nearest Opus Genetics' size, closest first, today.

Company	Price to book ratio
IRDOpus Genetics	n/m
NATRNatures Sunshine Products	1.3×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	2.4×
ABUSArbutus Biopharma	3.2×
AMPHAmphastar Pharmaceuticals	1.4×
LFVNLifevantage	2.2×
Peer median	2.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Opus Genetics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.